Key result
Hypertriglyceridemia-induced acute pancreatitis accounted for 19.99% of 56,617 acute pancreatitis cases and was associated with higher mortality (up to 20% vs 15.2%), severity, and recurrence rates compared to non-hypertriglyceridemia cases.
Why the study?
The study was conducted to comprehensively assess the epidemiology and identify risk factors associated with the severity and recurrence of hypertriglyceridemia-induced acute pancreatitis.
Systematic Review (n=56,617)
HTG-AP represents approximately 20% of acute pancreatitis cases globally, with rising prevalence in China, and is associated with more severe disease and higher recurrence rates than other etiologies.
Supports triglyceride assessment in AP; extends systematic evidence of HTG-AP's greater severity and China-specific rise.
This systematic review aims to comprehensively assess the epidemiology and identify risk factors associated with the severity and recurrence of hypertriglyceridemia-induced acute pancreatitis (HTG-AP). A search of PubMed, Web of Science, and Cochrane databases was conducted to identify all relevant randomized controlled trials (RCTs), prospective, or retrospective cohort studies on HTG-AP. Data related to epidemiology and risk factors for severity and recurrence of HTG-AP were extracted and analyzed. Seventy-seven studies met the inclusion criteria, comprising 1 RCT, 21 prospective studies, and 55 retrospective studies. A total of 56,617 acute pancreatitis (AP) patients were included, of which 19.99% were diagnosed with HTG-AP (n = 11,315). Compared to non-HTG-AP patients, HTG-AP patients were more likely to be male (68.7% vs. 57.3%) and younger (mean age 41.47 ± 4.32 vs. 50.25 ± 7.70 years). HTG-AP patients exhibited higher mortality rates (up to 20% vs. 15.2%), increased severity (8.3% to 100% vs. 3.8% to 47.2%), and higher recurrence rates (up to 64.8% vs. 23.3%). Analysis of temporal trends from 2002 to 2023 showed a range of HTG-AP prevalence in overall AP patients from 1.6% to 47.6%, with a slight upward trend that was not statistically significant (P = 0.1081). Regional analysis indicated relatively stable prevalence in North America (P = 0.5787), Europe (P = 0.0881), other regions (P = 0.738), while prevalence in China showed a significant increase (P = 0.0119). Thirteen studies investigated risk factors affecting HTG-AP severity, with elevated serum triglyceride (TG) levels associated with increased risk of complications such as pancreatic necrosis, systemic inflammatory response syndrome (SIRS), shock, and multi-organ failure. Additional factors including high neutrophil-to-lymphocyte ratio (NLR), elevated levels of amylase and C-reactive protein (CRP), hypocalcemia, and hypoalbuminemia were also implicated in HTG-AP severity. Smoking history, poor lipid control (TG > 3.1 mmol/L), or recurrent hypertriglyceridemia during follow-up were identified as potential predictors of HTG-AP recurrence. Our findings indicate a stable global prevalence of HTG-AP within AP patients, but a notable increase in China, possibly attributed to socio-economic and dietary factors.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2025) conducted a systematic review in Acute pancreatitis (n=56,617). Hypertriglyceridemia vs. Non-hypertriglyceridemia etiologies was evaluated on Proportion of hypertriglyceridemia-induced acute pancreatitis (HTG-AP) among acute pancreatitis patients. Hypertriglyceridemia-induced acute pancreatitis accounted for 19.99% of 56,617 acute pancreatitis cases and was associated with higher mortality (up to 20% vs 15.2%), severity, and recurrence rates compared to non-hypertriglyceridemia cases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: